Bispecific Anti-EGFR/C-Met Dosing Regimen for Resistance Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved therapeutics or therapeutic combinations to effectively treat epidermal growth factor receptor (EGFR)-expressing or hepatocyte growth factor receptor (c-Met)-expressing cancers, as these receptors often signal through the same pathways and are upregulated as a resistant mechanism for single agent treatment, leading to relapse or resistance to existing therapeutics.
Innovation Solution
Administering a bispecific anti-EGFR/c-Met antibody comprising specific HCDR and LCDR sequences, in combination with a 3rd generation EGFR tyrosine kinase inhibitor and chemotherapeutic agents like pemetrexed and carboplatin, at specific dosages and schedules, to target and inhibit both receptors, enhancing treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If single agent treatment targeting EGFR or c-Met is used, then treatment is simpler, but resistance and relapse occur due to upregulation of both receptors
Solution Approach 1:
The patent combines two therapeutic agents into a single fixed-dose combination product: (1) an anti-EGFR antibody (such as cetuximab or panitumumab) and (2) a c-Met inhibitor (such as tivantinib or capmatinib). This merging allows simultaneous targeting of both EGFR and c-Met pathways, preventing resistance mechanisms while maintaining ease of administration as a unified treatment regimen.
Solution Approach 2:
The fixed-dose combination product serves multiple functions simultaneously: it blocks EGFR signaling, inhibits c-Met activity, prevents compensatory upregulation of either receptor, and provides coordinated dual-pathway inhibition. This multi-functionality addresses the complexity of receptor crosstalk and resistance mechanisms in a single therapeutic intervention.
2Reliability
If combination therapy targeting both EGFR and c-Met is used, then treatment efficacy improves, but treatment complexity increases
Solution Approach 1:
The patent merges two separate therapeutic agents into a single fixed-dose combination product with predetermined ratios of anti-EGFR antibody and c-Met inhibitor. This eliminates the need for clinicians to separately prescribe, dose, and monitor two distinct medications, thereby reducing administrative and operational complexity while maintaining the therapeutic benefits of dual-pathway inhibition.
Solution Approach 2:
The fixed-dose combination establishes specific dosage parameters and administration schedules for the dual therapy, simplifying the complex task of determining appropriate doses for two separate agents. The predetermined ratios and dosing regimens transform a complex multi-parameter treatment into a standardized protocol with defined parameters.
Data Source
AI summary
Provided are methods of treating an epidermal growth factor receptor (EGFR)-expressing or hepatocyte growth factor receptor (c-Met)-expressing cancer in a subject in need thereof. The methods comprise administering to the subject a therapy comprising an isolated bispecific anti-EGFR/c-Met antibody, wherein the administration comprises a dose of about 1400-2100 mg, administered once per a 21-day cycle.